Late non-relapse mortality among adult autologous stem cell transplant recipients: A nation-wide analysis of 1482 patients transplanted in 1990-2003

European Journal of Haematology

Volumn 77, Issue 2, 2006, Pages 114-119

  Jantunen, E ^a   Itala M ^b   Siitonen, T ^c   Koivunen, E ^d   Leppa S ^e   Juvonen, E ^e   Kuittinen, O ^c   Lehtinen, T ^d   Koistinen, P ^c   Nyman, H ^e   Nousiainen, T ^a   Volin, L ^e   Remes, K ^b  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Autologous stem cell transplantation; Infection; Late mortality; Malignancy

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; BRONCHIOLITIS OBLITERANS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CARDIOMYOPATHY; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; INFECTION RISK; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECOND CANCER; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FINLAND; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; WHOLE-BODY IRRADIATION;

EID: 33745699623     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00685.x     Document Type: Article

References (27)

1. NIVISON-SMITH I, BRADSTOCK KF, DODDS AJ, et al. Haemopoietic stem cell transplantation in Australia and New Zealand, 1992-2001: progress report from the Australasian Bone Marrow Transplant Registry. Intern Med J 2005;35:18-27.
2. JANTUNEN E, ITÄLÄ M, LEHTINEN T, et al. Early treatment-related mortality in adult autologous stem cell transplant recipients: a nation-wide survey of 1482 transplanted patients. Eur J Haematol 2006;76:245-250.
3. ANDRE M, HENRY-AMAR M, BLAISE D, et al. Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 1998;92:1933-1940.
4. FRIEDBERG JW, NEUBERG D, STONE RM, et al. Outcome of patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3128-3135.
5. MICALLEF IN, LILLINGTON DM, APOSTOLIDIS J, et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000;18:947-955.
6. HOSING C, MUNSELL M, YAZJI S, et al. Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. Ann Oncol 2002;13:450-459.
7. FORREST DL, NEVILL TJ, NAIMAN SC, et al. Second malignancy following high-dose therapy and autologous stem cell transplantation: incidence and risk factor analysis. Bone Marrow Transplant 2003;32:915-923.
8. HOWE R, MICALLEF IN, INWARDS DJ, et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003;32:317-324.
9. BHATIA S, ROBINSON LL, FRANCISCO L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005;105:4215-4222.
10. KETTERER N, ESPINOUSE D, CHOMARAT M, et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med 1999;106:191-197.
11. ENGELHARD D, CORDONNIER C, SHAW PJ, et al. Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survey. Br J Haematol 2002;117:444-450.
12. CHEN CS, BOEKH M, SEIDEL K, et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32:515-522.
13. ORTEGA JJ, OLIVE T, DE HEREDIA CD, LLORT A. Second malignancies and quality of life after stem cell transplantation. Bone Marrow Transplant 2005;35:S83-S87.
14. BHATIA S, RAMSAY K, STEINBUCH M, et al. Malignant neoplasms following marrow transplantation. Blood 1996;87:3633-3639.
15. BEAUCHAMP-NICOUD A, FENEUX D, BAYLE C, et al. Therapy-related myelodysplasia and/or acute myeloid leukaemia after autologous haematopoietic progenitor cell transplantation in a prospective single centre cohort of 221 patients. Br J Haematol 2003;122:109-117.
16. PEDERSEN-BJERGAARD J, PEDERSEN M, MYHRE J, GEISLER C. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997;11:1654-1660.
17. KRISHNAN A, BHATIA S, SLOVAK ML, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588-1593.
18. PARK S, BRICE P, NOGUERRA ME, et al. Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2000;26:321-326.
19. LENZ G, DREYLING M, SCHIEGNITZ E, et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomised trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004;22:4926-4933.
20. BROWN JR, YECKES H, FRIEDBERG JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005;23:2208-2214.
21. MILLIGAN DW, RUIZ DE ELVIRA MC, KOLB HJ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol 1999;106:1020-1026.
22. HARRISON CN, GREGORY W, HUDSON GV, et al. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer 1999;81:476-483.
23. MILLIGAN DW. Secondary leukaemia and myelodysplasia after autografting for lymphoma: is the transplant to blame? Leuk Lymphoma 2000;39:223-228.
24. LAVOIE JC, CONNORS JM, PHILLIPS GL, et al. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood 2005;106:1473-1478.
25. BHATIA S, LOUIE AD, BHATIA RA, et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001;19:464-471.
26. BAKER KS, DEFOR TE, BURNS LJ, et al. New malignancies after blood and marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003;21:1352-1358.
27. LJUNGMAN P, ENGELHARD D, DE LA CAMERA R, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Disease Working Party of EBMT. Bone Marrow Transplant 2005;35:737-746.